JP2015514722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514722A5 JP2015514722A5 JP2015504988A JP2015504988A JP2015514722A5 JP 2015514722 A5 JP2015514722 A5 JP 2015514722A5 JP 2015504988 A JP2015504988 A JP 2015504988A JP 2015504988 A JP2015504988 A JP 2015504988A JP 2015514722 A5 JP2015514722 A5 JP 2015514722A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- agents
- val
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 76
- 150000001875 compounds Chemical class 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 38
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 35
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 34
- 125000002015 acyclic group Chemical group 0.000 claims description 33
- 125000001931 aliphatic group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 230000015572 biosynthetic process Effects 0.000 claims description 32
- 238000003786 synthesis reaction Methods 0.000 claims description 30
- 229920000642 polymer Polymers 0.000 claims description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims description 24
- 229920001223 polyethylene glycol Polymers 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- -1 oleosomes Substances 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 210000003491 skin Anatomy 0.000 claims description 13
- 201000004624 Dermatitis Diseases 0.000 claims description 12
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 12
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 6
- 210000001789 adipocyte Anatomy 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000000693 micelle Substances 0.000 claims description 6
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000037303 wrinkles Effects 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 5
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 206010051246 Photodermatosis Diseases 0.000 claims description 5
- 208000012641 Pigmentation disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 5
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 230000037307 sensitive skin Effects 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 102000010637 Aquaporins Human genes 0.000 claims description 4
- 108010063290 Aquaporins Proteins 0.000 claims description 4
- 102000016942 Elastin Human genes 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 4
- 206010015150 Erythema Diseases 0.000 claims description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 229920002549 elastin Polymers 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 230000003779 hair growth Effects 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 210000002510 keratinocyte Anatomy 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 230000003061 melanogenesis Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 239000002088 nanocapsule Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000008845 photoaging Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 208000005141 Otitis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 208000019258 ear infection Diseases 0.000 claims description 3
- 239000004530 micro-emulsion Substances 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 claims description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims description 2
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims description 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 2
- 235000007173 Abies balsamea Nutrition 0.000 claims description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 claims description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 208000028185 Angioedema Diseases 0.000 claims description 2
- 108090000991 Aquaporin 3 Proteins 0.000 claims description 2
- 102100037332 Aquaporin-3 Human genes 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 239000004857 Balsam Substances 0.000 claims description 2
- 208000035985 Body Odor Diseases 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 2
- 208000035484 Cellulite Diseases 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 102000004237 Decorin Human genes 0.000 claims description 2
- 108090000738 Decorin Proteins 0.000 claims description 2
- 102000000541 Defensins Human genes 0.000 claims description 2
- 108010002069 Defensins Proteins 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 229940123457 Free radical scavenger Drugs 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 claims description 2
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 244000018716 Impatiens biflora Species 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229940127408 Melanin Synthesis Inhibitors Drugs 0.000 claims description 2
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 206010029216 Nervousness Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 2
- 102000000536 PPAR gamma Human genes 0.000 claims description 2
- 108010016731 PPAR gamma Proteins 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033733 Papule Diseases 0.000 claims description 2
- 206010049752 Peau d'orange Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 claims description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 2
- 229940123575 Protein synthesis stimulant Drugs 0.000 claims description 2
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 claims description 2
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010037888 Rash pustular Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- 108050002485 Sirtuin Proteins 0.000 claims description 2
- 102000011990 Sirtuin Human genes 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 208000031439 Striae Distensae Diseases 0.000 claims description 2
- 206010043189 Telangiectasia Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010046914 Vaginal infection Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 208000035868 Vascular inflammations Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000003915 air pollution Methods 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000001166 anti-perspirative effect Effects 0.000 claims description 2
- 230000002682 anti-psoriatic effect Effects 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 229940125687 antiparasitic agent Drugs 0.000 claims description 2
- 239000003213 antiperspirant Substances 0.000 claims description 2
- 239000003908 antipruritic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000003899 bactericide agent Substances 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 2
- 229920001222 biopolymer Polymers 0.000 claims description 2
- 238000010352 biotechnological method Methods 0.000 claims description 2
- 239000007844 bleaching agent Substances 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 235000009120 camo Nutrition 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000019522 cellular metabolic process Effects 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- 235000005607 chanvre indien Nutrition 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 230000011382 collagen catabolic process Effects 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000002781 deodorant agent Substances 0.000 claims description 2
- 239000007854 depigmenting agent Substances 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 230000028023 exocytosis Effects 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 238000009313 farming Methods 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 239000013003 healing agent Substances 0.000 claims description 2
- 239000011487 hemp Substances 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 229940100601 interleukin-6 Drugs 0.000 claims description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 2
- 229940096397 interleukin-8 Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 230000004130 lipolysis Effects 0.000 claims description 2
- 230000002366 lipolytic effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000008099 melanin synthesis Effects 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 230000004089 microcirculation Effects 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000004118 muscle contraction Effects 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 239000002353 niosome Substances 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000003711 photoprotective effect Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 230000019612 pigmentation Effects 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 230000001012 protector Effects 0.000 claims description 2
- 208000029561 pustule Diseases 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 230000000552 rheumatic effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 229940125723 sedative agent Drugs 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000002047 solid lipid nanoparticle Substances 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 210000000434 stratum corneum Anatomy 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 208000009056 telangiectasis Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 235000015961 tonic Nutrition 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 229960000716 tonics Drugs 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000008728 vascular permeability Effects 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 7
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 7
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 239000004744 fabric Substances 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010037083 Prurigo Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010068172 Anal pruritus Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000011219 Netherton syndrome Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000013612 Parathyroid disease Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039986 Senile pruritus Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000022560 parathyroid gland disease Diseases 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624653P | 2012-04-16 | 2012-04-16 | |
| US61/624,653 | 2012-04-16 | ||
| ES201230567 | 2012-04-16 | ||
| ESP201230567 | 2012-04-16 | ||
| PCT/EP2013/057939 WO2013156493A1 (en) | 2012-04-16 | 2013-04-16 | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514722A JP2015514722A (ja) | 2015-05-21 |
| JP2015514722A5 true JP2015514722A5 (enExample) | 2016-06-09 |
| JP6470680B2 JP6470680B2 (ja) | 2019-02-13 |
Family
ID=49382956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504988A Active JP6470680B2 (ja) | 2012-04-16 | 2013-04-16 | 皮膚および／または粘膜の処置および／またはケアのための組成物ならびに化粧品組成物または医薬組成物におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9725483B2 (enExample) |
| EP (1) | EP2838547B1 (enExample) |
| JP (1) | JP6470680B2 (enExample) |
| KR (1) | KR102113998B1 (enExample) |
| CN (1) | CN104254339B (enExample) |
| AU (1) | AU2013248301B2 (enExample) |
| BR (1) | BR112014025621B1 (enExample) |
| WO (1) | WO2013156493A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486408B2 (en) * | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| US11039997B2 (en) * | 2005-12-27 | 2021-06-22 | Ruth-Maria Korth | Cosmetic, dermatic, protective compositions comprising phospholipids, lecithins with peptides and at least one acetylating compound |
| HK1219477A1 (zh) | 2013-03-21 | 2017-04-07 | Sanofi-Aventis Deutschland Gmbh | 合成含有乙内酰脲的肽产物 |
| SG11201506885UA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of cyclic imide containing peptide products |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| US10242871B2 (en) * | 2014-10-21 | 2019-03-26 | Nissan Chemical Industries, Ltd. | Resist underlayer film-forming composition including a compound having an amino group protected with a tert-butoxycarbonyl group |
| JP6046849B1 (ja) * | 2015-07-21 | 2016-12-21 | ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 | 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法 |
| KR20180090251A (ko) * | 2015-09-28 | 2018-08-10 | 아주라 오프탈믹스 엘티디 | 마이봄샘 지질 분비를 증가시키기 위한 티올 및 이황화물 함유 약제 |
| US10695285B2 (en) * | 2015-11-26 | 2020-06-30 | Mp2 Cosmetic Solutions Sarl | Anti-pollution complex comprising calendula extracts and an aqueous extract of lilum candidum bulb and uses thereof |
| CN108495646B (zh) * | 2015-12-10 | 2022-07-08 | 路博润先进材料公司 | 用于治疗和/或护理皮肤、毛发、指甲和/或粘膜的化合物 |
| HK1257429A1 (zh) | 2016-02-04 | 2019-10-18 | ALASTIN Skincare, Inc. | 用於侵入性和非侵入性程序性护肤的组合物和方法 |
| US10744174B1 (en) | 2016-03-16 | 2020-08-18 | Robert Alonso | Composition(s) and method(s) for topically treating pain |
| EP3442519A4 (en) | 2016-04-14 | 2019-12-04 | Azura Opthalmics Ltd. | SELDISULFID COMPOSITIONS FOR USE IN THE TREATMENT OF THE MEIBOM DRESSING DYSFUNCTION |
| US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| WO2018102508A1 (en) * | 2016-11-30 | 2018-06-07 | Lubrizol Advanced Materials, Inc. | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes |
| EP3378463A1 (fr) | 2017-03-20 | 2018-09-26 | Total Marketing Services | Utilisation non-therapeutique d'une huile hydrocarbonee biodegradable |
| BR112020000123A2 (pt) * | 2017-07-04 | 2020-07-07 | Lubrizol Advanced Materials, Inc. | composto, uso de um composto, composição cosmética, e, método para cuidado e/ou tratamento cosmético não terapêutico da pele, cabelos, unhas e/ou membranas mucosas |
| KR102757675B1 (ko) | 2017-08-03 | 2025-01-20 | 앨러스틴 스킨케어, 인크. | 피부 이완 및 신체 윤곽의 개선을 위한 조성물 및 방법 |
| FR3078891B1 (fr) * | 2018-03-16 | 2020-12-25 | Centre Nat Rech Scient | Utilisation d’un extrait d’ilex aquifolium pour le traitement des desordres de la pigmentation et pour le blanchiment de la peau |
| US10835504B2 (en) | 2018-04-18 | 2020-11-17 | G&S Laboratories, Inc. | Compositions to treat anal itch |
| CN108785164B (zh) * | 2018-07-03 | 2021-09-14 | 博凯药业有限公司 | 滋润护肤乳及其制备方法和应用 |
| WO2020028694A1 (en) | 2018-08-02 | 2020-02-06 | ALASTIN Skincare, Inc. | Liposomal compositions and methods of use |
| CN109125107B (zh) * | 2018-09-20 | 2022-02-01 | 深圳市维琪医药研发有限公司 | 一种有效改善和修复面部激素依赖性皮炎的多肽组合物 |
| JP7686563B2 (ja) * | 2019-02-08 | 2025-06-02 | ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド | 皮膚、毛髪、爪および／または粘膜の処置および／またはケアに有用な化合物 |
| EP3927349A1 (en) | 2019-02-18 | 2021-12-29 | Mary Kay, Inc. | Topical skin compositions for treating rosacea and skin redness |
| US11083766B2 (en) * | 2019-05-06 | 2021-08-10 | Charsire Biotechnology Corp. | Uses of soybean seed extract composition for alleviating cancer pain and/or treating cancer skin inflammation |
| TWI722443B (zh) | 2019-05-30 | 2021-03-21 | 財團法人工業技術研究院 | 用於照護及/或保養皮膚與延緩及/或抑制皮膚老化的生醫組成物及其用途 |
| CN112098569B (zh) * | 2019-06-17 | 2021-09-24 | 国药集团同济堂（贵州）制药有限公司 | 一种威灵仙提取物的制备方法及其质量测定方法 |
| US11529300B2 (en) * | 2019-07-03 | 2022-12-20 | Jamrm, Llc | Formulations for enhancing skin firmness, density and thickness |
| WO2021102072A1 (en) * | 2019-11-19 | 2021-05-27 | Rythera Therapeutics, Inc. | Composition and method for skin treatment |
| CN115279458A (zh) | 2020-01-10 | 2022-11-01 | 阿祖拉眼科有限公司 | 组合物和敏感性说明 |
| KR102221141B1 (ko) * | 2020-08-10 | 2021-02-26 | 주식회사 달담 | 여드름 피부 개선용 화장료 조성물 |
| KR102266613B1 (ko) * | 2020-09-21 | 2021-06-18 | 자안바이오 주식회사 | 항염증 활성을 갖는 신규한 펩티드 및 이의 용도 |
| US20220218584A1 (en) * | 2021-01-13 | 2022-07-14 | Allergan Sales, Llc | Topical composition and method of use |
| IT202100016622A1 (it) * | 2021-06-24 | 2022-12-24 | Thinking Woman Srl | Formulazione cosmetica con attivita’ antimicrobica sinergica |
| EP4442696A4 (en) * | 2021-12-31 | 2025-04-30 | Shenzhen Winkey Technology Co., Ltd | HEXAPEPTIDE, COSMETIC COMPOSITION OR PHARMACEUTICAL COMPOSITION THEREOF AND USE OF HEXAPEPTIDE |
| KR102495269B1 (ko) * | 2022-04-06 | 2023-02-06 | 이해경 | 가교 히알루론산 함유 피부 필러 조성물 및 그 제조방법 |
| KR102643334B1 (ko) * | 2022-08-23 | 2024-03-05 | 주식회사 큐에이치바이오 | 가교 히알루론산 및 생체 적합성 미립자를 포함하는 피부 필러 조성물, 및 그 제조방법 |
| KR102649055B1 (ko) * | 2022-09-22 | 2024-03-20 | 주식회사 큐에이치바이오 | 히알루론산-글라이신 하이드로겔 및 생체 적합성 미립자를 포함하는 피부 필러 조성물, 및 그 제조방법 |
| CN115364039B (zh) * | 2022-09-28 | 2023-07-25 | 佛山天韵化妆品科技有限公司 | 一种痤疮皮肤修复组合物及其应用 |
| CN116731111A (zh) * | 2022-10-14 | 2023-09-12 | 深圳市维琪科技股份有限公司 | 合成肽及其组合物和用途 |
| CN115844756A (zh) * | 2022-12-07 | 2023-03-28 | 麦吉丽生物科技有限公司 | 一种具有改善皮肤光泽的组合物、脂质体及其制备方法和应用 |
| WO2025123114A1 (pt) * | 2023-12-15 | 2025-06-19 | Chemyunion Ltda | Composição cosmética, cosmecêutica e/ou farmacêutica, usos e métodos |
| KR102752384B1 (ko) * | 2024-01-16 | 2025-01-10 | 주식회사 큐에이치바이오 | 에피브로모히드린-가교 히알루론산 및 생체 적합성 미립자를 포함하는 피부 필러 조성물, 및 그 제조방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807182B2 (en) * | 1996-12-31 | 2010-10-05 | Colorado State University Research Foundation | Early detection of mycobacterial disease using peptides |
| US20040071656A1 (en) * | 2001-12-26 | 2004-04-15 | Felix Wieland | Modulation of heat-shock-protein-based immunotherapies |
| RU2423375C2 (ru) * | 2005-07-26 | 2011-07-10 | СиЭмЭс ПЕПТАЙДЗ ПЭЙТЕНТ ХОЛДИНГ КОМПАНИ ЛИМИТЕД | Новые биологически активные пептиды и их новое применение |
| JP5167155B2 (ja) * | 2006-03-09 | 2013-03-21 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法 |
| JP5065635B2 (ja) * | 2006-08-08 | 2012-11-07 | ロート製薬株式会社 | 新規ペプチド |
| CN101855235B (zh) * | 2007-10-29 | 2013-04-24 | 赫里克斯生物医疗公司 | 保护性皮肤护理四肽 |
| ES2324192B1 (es) * | 2008-01-30 | 2010-06-17 | PUIG BEAUTY & FASHION GROUP, S.L. | Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas. |
| ES2330291B1 (es) * | 2008-02-29 | 2010-10-18 | Lipotec Sa | Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. |
| ES2342754B1 (es) * | 2008-10-03 | 2011-05-11 | Lipotec, S.A. | Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas, cuero cabelludo y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. |
| ES2349972B1 (es) * | 2009-02-16 | 2011-11-24 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas. |
| US20110086806A1 (en) * | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Polypeptides that Bind IL-23R |
| US8420387B2 (en) * | 2009-11-06 | 2013-04-16 | Agrivida, Inc. | Intein-modified enzymes, their production and industrial applications |
| EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| ES2625847T3 (es) * | 2011-11-04 | 2017-07-20 | Lipotec, S.A. | Péptidos que inhiben la actividad de receptores activados y su uso en composiciones cosméticas o farmacéuticas |
| US9046530B2 (en) * | 2011-12-02 | 2015-06-02 | Board Of Regents, The University Of Texas System | Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection |
-
2013
- 2013-04-16 WO PCT/EP2013/057939 patent/WO2013156493A1/en not_active Ceased
- 2013-04-16 US US14/391,472 patent/US9725483B2/en active Active
- 2013-04-16 AU AU2013248301A patent/AU2013248301B2/en active Active
- 2013-04-16 JP JP2015504988A patent/JP6470680B2/ja active Active
- 2013-04-16 BR BR112014025621-7A patent/BR112014025621B1/pt active IP Right Grant
- 2013-04-16 EP EP13716017.2A patent/EP2838547B1/en active Active
- 2013-04-16 KR KR1020147032014A patent/KR102113998B1/ko active Active
- 2013-04-16 CN CN201380020197.9A patent/CN104254339B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514722A5 (enExample) | ||
| JP2016502550A5 (enExample) | ||
| EP2651428B1 (en) | Pgc-1alpha-modulating peptides | |
| AU2009218680B2 (en) | Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors | |
| US9511010B2 (en) | Compounds useful in the treatment and/or care of the skin, hair and/or mucous membranes and their cosmetic or pharmaceutical compositions | |
| JP6470680B2 (ja) | 皮膚および／または粘膜の処置および／またはケアのための組成物ならびに化粧品組成物または医薬組成物におけるその使用 | |
| JP2019502677A5 (enExample) | ||
| JP2015514721A5 (enExample) | ||
| JP2016519105A5 (enExample) | ||
| JP2015514124A5 (enExample) | ||
| EP3171869B1 (en) | Active ingredient comprising a mixture of unsaturated dicarboxylic fatty acids, compositions comprising said ingredient and cosmetic or dermatological uses | |
| US11576938B2 (en) | Extracts of microalgae and plants for regulating sebum production | |
| JP2016535035A5 (enExample) | ||
| JP2018500279A5 (enExample) | ||
| TW201333045A (zh) | 用來抑制經活化受體之胜肽及其於化妝或醫藥組成物中之用途 | |
| EP3277254B1 (en) | Topical cosmetic treatment of skin and scalp and corresponding active ingredient based on an extract of apium graveolens | |
| BR112020000123A2 (pt) | composto, uso de um composto, composição cosmética, e, método para cuidado e/ou tratamento cosmético não terapêutico da pele, cabelos, unhas e/ou membranas mucosas | |
| JP2015514125A5 (enExample) | ||
| ES2612237T3 (es) | Exopolisacárido para el tratamiento y/o cuidado de la piel, membranas de mucosas y/o uñas | |
| CN104337705B (zh) | 含有葡糖酸内酯和乳糖酸的化妆品组合物 | |
| JP2024543222A (ja) | 脂肪分解ペプチド | |
| JPWO2000064926A1 (ja) | メラノサイト刺激ホルモン阻害剤 | |
| CN116528825A (zh) | 一种四肽衍生物及其美容组合物或药用组合物和用途 | |
| CN119112923A (zh) | 络丝蛋白和/或vegf-c的生产和/或活性促进剂及使用该促进剂的皮肤外用剂 | |
| HK1233175A1 (en) | Active ingredient comprising a mixture of unsaturated dicarboxylic fatty acids, compositions comprising said ingredient and cosmetic or dermatological uses |